(NASDAQ: LXRX) Lexicon Pharmaceuticals's forecast annual revenue growth rate of -32.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.27%.
Lexicon Pharmaceuticals's revenue in 2025 is $58,432,000.On average, 7 Wall Street analysts forecast LXRX's revenue for 2025 to be $18,811,341,988, with the lowest LXRX revenue forecast at $17,948,996,493, and the highest LXRX revenue forecast at $19,498,165,833. On average, 7 Wall Street analysts forecast LXRX's revenue for 2026 to be $4,540,305,357, with the lowest LXRX revenue forecast at $2,142,599,679, and the highest LXRX revenue forecast at $10,493,142,083.
In 2027, LXRX is forecast to generate $10,242,760,268 in revenue, with the lowest revenue forecast at $2,241,444,168 and the highest revenue forecast at $25,908,521,724.